Use of anticoagulants in AF patients with renal impairment What is the point of view of a cardiologist?
|
|
- Corey Cameron
- 6 years ago
- Views:
Transcription
1 Use of anticoagulants in AF patients with renal impairment What is the point of view of a cardiologist? Prof. Dan Atar, MD Dept. of Cardiology B Oslo University Hospital, Norway Vice-President of the ESC ( ) Member, ESC Media Committee ( ) ESC Congress Program Committee ( ) Tallinn
2 Prof. Dan Atar Disclosures Co-author of the 2010, 2012 and 2016 ESC Guidelines on Atrial Fibrillation and 2012 ESC STEMI Guidelines, as well as the 2018 Universal Definition of AMI GL. Steering Committee member, National Coordinator for Norway, and Co-author of ACTIVE, RELY, ARISTOTLE, AVERROES, APPRAISE, GARFIELD, ENGAGE-AF, XANTUS, RE-ALIGN, RE-VERSE, ARTESIA, NOAH, ENTRUST-AF-PCI, REPORT-AF, RE-SONANCE, REPORT-HF, PARAGON, VICTORIA. Adjudication Committee member for the AVRO and Roxadustat trials, DSMB for the CHILL-MI, OPTIMUM, LUPUS, BETA-3 and HOMAGE trials. Chair of the FIRE and MITOCARE trial (EU-FP7 fundet). Fees, honoraria from Boehringer- Ingelheim, Bayer, BMS/Pfizer, Cardiome, Astra-Zeneca, MSD, Sanofi-Aventis, Amgen.
3 QUIZ
4 Quiz what is the correct answer? How many registered participants were at the ESC congress 2017 in Barcelona? A: B: C: D: E:
5 Quiz what is the correct answer? 5 days before the ESC congressen 2017, Barcelona was targeted by a devastating terrorism event. How many of the registered participants withdrew? A: 30 B: 115 C: 412 D: 731 E: 1316
6 Quiz what is the correct answer? Which country had most participants and abstracts at the ESC congress 2017 in Barcelona? A: Tyskland B: Frankrike C: Japan D: Spania E: USA
7 Prelude on Atrial Fibrillation
8 Differences in 2-year outcomes according to type of AF Professor Dan Atar Oslo University Hospital Ullevål and University of Oslo, Oslo, Norway
9 Background The type of atrial fibrillation (AF) has not been established as a major predictor of stroke or death, with conflicting reports in the literature 1-4 Therefore, AF burden, defined according to each type of AF, has not been factored into the guidance for clinical decision making 5,6 1. Banerjee A. et al Int J Cardiol. 2013; 167: Vanassche T. et al European Heart Journal. 2015; 36: 281-7a 3. Steinberg B.A. et al European Heart Journal. 2015; 36: Senoo K. et al Stroke. 2015; 46: Kirchhof P. et al European Heart Journal. 2016; 37: January C.T. et al Circulation. 2014; 130:
10 Stroke and systemic embolic event (SEE) occurred less frequently in the patients with paroxysmal atrial fibrillation (AF) (1.49%/y), as compared with persistent (1.83%/y; HR, 0.79; 95% CI, ; P=0.015) and permanent AF (1.95%/y; HR, 0.79; 95% CI, ; P=0.004). Mark S. Link et al. Circ Arrhythm Electrophysiol. 2017;10:e Courtesy Prof. M. Rosenkvist
11 Objectives To analyse outcomes over 2 years after diagnosis of AF by type of AF and by antithrombotic therapy Methods We analysed baseline characteristics, antithrombotic therapy, and 2-year incidence of outcomes in patients classified as having paroxysmal, persistent, or permanent AF Cohorts 1 4, N=28,628
12 Clinical characteristics of patients Paroxysmal AF (n=10,473) Persistent AF (n=6020) Permanent AF (n=5117) Age 75 yrs, % Mean (SD) 68.5 (11.7) 69.1 (10.9) 72.6 (10.6) Female, % BMI 30 kg/m 2, % NYHA Class III IV CHF, % ACS, % LVEF <40%, % Prior stroke/tia, % Carotid occlusive disease, % Cohorts 1 4, N=28,628
13 Antithrombotic treatment patterns VKA±AP FXaI±AP DTI±AP Proportion of patients, % ,1 26,8 7,0 13,1 38,0 9,0 8,3 19,7 19,7 7,7 5,8 9,8 9,0 53,9 57,1 0 Paroxysmal AF (n=10,473) Persistent AF (n=6020) Permanent AF (n=5117) AP, antiplatelet; CHF, congestive heart failure; DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K antagonists Cohorts 1 4, N=28,628
14 Adjusted HRs for 2-year clinical outcomes according to type of AF HRs were adjusted for anticoagulant treatment and the following baseline factors: age, gender, race, smoking, diabetes, hypertension, stroke/transient ischaemic attack/systemic embolism, history of bleeding, cardiac failure, vascular disease, moderate-to-severe CKD, and heavy alcohol consumption (only for major bleeding)
15 Conclusions Patients with paroxysmal AF were less likely to be prescribed AC therapy (with or without AP therapy) than those with persistent or permanent AF Persistent and permanent AF were associated with higher mortality risk compared with paroxysmal AF, but had similar adjusted risks of stroke/se and major bleeding during 2 years of follow-up
16 Clinical implications The finding of similar adjusted stroke rates in patients with paroxysmal AF as compared to those with persistent or permanent AF has several implications: It emphasises the need for early detection of silent and unnoticed paroxysmal AF It underscores the recommendation to apply the same stroke prevention strategies to paroxysmal AF as to the other types of AF
17 Use of anticoagulants in AF patients with renal impairment
18 ESRD
19 Renal impairment is common among AF patients and is associated with increased risk of adverse outcomes Distribution of patients with AF according to renal function Leiden Anticoagulation Clinic (n=5,039; ) 1 AURICULA Registry, Malmö (n=2,603; ) % 34.2% 80 Using Different egfr Cut-off Values % of Patients % % of Patients % % 0.8% % 4.3% > <60 <45 <30 egfr, ml/min/1.73 m 2 (MDRD formula) egfr, ml/min/1.73 m 2 (MDRD formula) egfr: estimated glomerular filtration rate; MDRD: modification of diet in renal disease. 1 Kooiman et al. J Thromb Haemost 2011;9:1652-3; 2 Jönsson et al. Thromb Res 2011;128:341-5.
20 Chronic kidney disease increases the risk of stroke, bleeding, MI and all-cause death in AF patients Risk of Events in NVAF Patients with Non-end-stage CKD (n=3,587) or with CKD Requiring Renal Replacement Therapy (n=901) vs. NVAF Patients with No Renal Disease (n=127,884) Danish Registry ( ) Reference: Patients with no renal disease HR (95% CI)* Stroke or Systemic Thromboembolism Non-end-stage CKD 1.49 (1.38; 1.59) CKD requiring renal replacement therapy 1.83 (1.57; 2.14) Bleeding Non-end-stage CKD 2.24 (2.10; 2.38) CKD requiring renal replacement therapy 2.70 (2.38; 3.07) Myocardial Infarction Non-end-stage CKD 2.00 (1.86; 2.16) CKD requiring renal replacement therapy 3.00 (2.58; 3.50) Death from Any Cause Non-end-stage CKD 2.37 (2.30; 2.44) CKD requiring renal replacement therapy 3.35 (3.13; 3.58) *Adjusted for baseline characteristics. Adapted from Olesen et al. N Engl J Med 2012;367:
21 Extent of renal excretion varies between the different NOACs which could influence their safety in patients with impaired renal function Heidbuchel et al. Europace 2013; 15: (EHRA guidelines)
22 Chang M et al. Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Poster presented at ACCP 2012 Eliquis SPC 2013 Eliquis EMA assessment report Sept 2012 Apixaban Concentration Time Profiles Concentration (ng/ml) 1000 Apixaban concentration is fairly similar regardless of renal impairment level Severe renal impairment Moderate renal impairment Mild renal impairment Normal renal function Time (h)
23 Apixaban is the only NOAC to demonstrate superiority vs. warfarin in stroke/se prevention, reduction of major bleeding and all cause mortality (ARISTOTLE) Superior stroke/systemic embolism prevention 21% RRR p=0.01 Superior profile in reducing major bleeding 31% RRR p<0.001 Superior reduction in all-cause mortality 11% RRR p= ,0% Event rate (%/year) 4,0% 3,0% 2,0% 1,0% 1,60% 265/9081 1,27% 212/9120 3,09% 462/9052 2,13% 327/9088 3,94% 669/9081 3,52% 603/9120 0,0% Primary efficacy endpoint Primary safety endpoint Key secondary endpoint Warfarin (target INR ) 1 Adapted from Granger CB et al. N Engl J Med 2011;365: Apixaban
24 ARISTOTLE: The benefits of Apixaban vs. warfarin were maintained in patients with impaired renal function; these patients appeared to show the greatest reduction in major bleeding vs. warfarin Apixaban %/yr (n) Warfarin %/yr (n) Hazard Ratio (95% CI) P Value for Interaction Stroke/SE Cockcroft-Gault (egfr ml/min) > (70) 1.12 (79) > (87) 1.69 (116) (54) 2.67 (69) Major Bleeding Cockcroft-Gault (egfr ml/min) > (96) 1.84 (119) > (157) 3.21 (199) (73) 6.44 (142) NOTE: Patients with calculated creatinine clearance of <25 ml /minute were excluded from ARISTOTLE egfr=estimated glomerular filtration rate. Hohnloser SH et al. Eur Heart J. 2012;: Apixaban Better Warfarin Better
25 ARISTOTLE: In elderly patients ( 75 years) the benefits of Apixaban vs. warfarin were consistent across the range of estimated glomerular filtration rate No. of patients 75 years Apixaban %/yr (n) Warfarin %/yr (n) Hazard Ratio (95% CI) P Value for Interaction Stroke/SE Cockcroft-Gault (egfr ml/min) > (8) 2.16 (11) > (39) 1.70 (45) > (28) 2.69 (44) (3) 5.57 (9) Major Bleeding Cockcroft-Gault (egfr ml/min) > (11) 3.39 (15) > (85) 4.45 (104) > (47) 6.27 (87) (7) 13.4 (17) NOTE: Patients with calculated creatinine clearance of <25 ml /minute were excluded from ARISTOTLE 0,0625 0,125 0,25 0,5 1 2 egfr=estimated glomerular filtration rate. Halvorsen S et al. European Heart J doi: /eurheartj/ehu046 epub February Apixaban Better Warfarin Better
26 AVERROES: The efficacy and safety of Apixaban vs ASA was maintained in patients with NVAF and moderate renal impairment 1 Stroke / SE Apixaban ASA % / yr (No. of events / No. of patients) egfr 60 ml/min 1.7% (34/1917) 2.8% (60/1911) egfr ml/min 1.8% (17/857) 5.6% (51/840) Major Bleeding egfr 60 ml/min 0.9% (19/1917) 0.8% (18/1911) egfr ml 2.5% (24/857) 2.2% (20/840) All-cause mortality egfr 60 ml/min 2.3% (49/1917) 3.3% (71/1911) egfr ml/min 6.2% (59/857) 7.1% (66/840) NOTE: Patients with calculated creatinine clearance of <25 ml /minute were excluded from AVERROES Hazard Ratio (95% CI) Apixaban better ASA better 2.0 P value Interaction: 0.10 Interaction: 0.82 Interaction: 0.39 Event rates for 70 patients with stage IV CKD assigned to apixaban (n =31) versus aspirin (n =39) primary events : 0% per year (n= 0) vs.5% per year (n= 2); major hemorrhage: 3.0% per year (n =1) vs. 2.5% per year (n = 1); Death: 9.1% per year (n =3) vs. 7.4% per year (n =3). egfr, estimated glomerular filtration rate. egfr ml/min/1.73 m 2 : stage III chronic kidney disease (CKD); 1 Adapted from Eikelboom JW et al. J Stroke Cerebrovasc Dis 2012;21:
27 Dabigatran 110mg: Outcomes of RE-LY according to renal function 1 Dabigatran Warfarin 110 mg BID %/yr (no. of events) Hazard ratio (95% CI) P value for interaction Stroke / SE egfr 80 ml/min 0.88 (35) 1.05 (41) egfr 50-<80 ml/min 1.69 (94) 1.83 (103) egfr <50 ml/min 2.32 (52) 2.70 (57) Major bleeding egfr 80 ml/min 1.48 (59) 2.43 (95) egfr 50-<80 ml/min 2.84 (158) 3.70 (209) egfr <50 ml/min 5.45 (122) 5.49 (116) NOTE: Patients with calculated creatinine clearance of <30 ml /minute were excluded from RE-LY GFR: glomerular filtration rate, BID: twice-daily GFR estimation according to Cockcroft-Gault method Dabigatran better Warfarin better 1. Hijazi et al. Circulation Dec 9. [Epub ahead of print]
28 Dabigatran 150mg: Outcomes of RE-LY according to renal function 1 Dabigatran Warfarin 150 mg BID %/yr (no. of events) Hazard ratio (95% CI) P value for interaction Stroke / SE egfr 80 ml/min 0.71 (28) 1.05 (41) egfr 50-<80 ml/min 1.25 (70) 1.83 (103) egfr <50 ml/min 1.53 (36) 2.70 (57) Major Bleeding egfr 80 ml/min 2.04 (81) 2.43 (95) egfr 50-<80 ml/min 3.35 (188) 3.70 (209) egfr <50 ml/min 5.50 (129) 5.49 (116) NOTE: Patients with calculated creatinine clearance of <30 ml /minute were excluded from RE-LY GFR: glomerular filtration rate, BID: twice-daily GFR estimation according to Cockcroft-Gault method Dabigatran better Warfarin better 1. Hijazi et al. Circulation Dec 9. [Epub ahead of print]
29 Rivaroxaban: Outcomes of ROCKET-AF according to renal function 1 Rivaroxaban Warfarin P value for Event rates per 100 patientyears of follow-up Hazard ratio (95% CI) interaction Stroke / SE 0.76 CrCl 50 ml/min * CrCl ml/min Major bleeding 0.48 CrCl 50 ml/min CrCl ml/min Rivaroxaban better Warfarin better NOTE: Patients with calculated creatinine clearance of <30 ml /minute were excluded from ROCKET-AF 1. Fox et al. Eur Heart J. 2011;32:
30 EHRA Practical Guide (2013) Apixaban demonstrated a lower overall rate of major bleeding compared to VKA, and [ ] the increase in the rate of bleeding by renal dysfunction was significantly less than with VKA A similar benefit/risk ratio of NOACs vs. VKAs was seen with a reduced dose rivaroxaban (15 mg qd) in patients with renal impairment (CrCl <50 ml/min) [ ] dabigatran, which is primarily cleared renally, may not be the NOAC of first choice in patients with known CKD, especially stage III or higher Heidbuchel et al. Europace (2013) 15,
31 Stroke/SE and major bleeding risk for subgroups of patients with stage III CKD* from trials comparing NOACs and warfarin Stroke/SE Dabigatran 110 mg bid 0.77 ( ) Dabigatran 150 mg bid Rivaroxaban 15 mg qd Apixaban 2.5/5.0 mg bid 0.55 ( ) 0.86 ( ) 0.79 ( ) Major bleeding Dabigatran 110 mg bid Dabigatran 150 mg bid Rivaroxaban 15 mg qd Apixaban 2.5/5.0 mg bid 0.99 ( ) 1.03 ( ) 0.95 ( ) 0.50 ( ) New oral anticoagulant better Warfarin better New oral anticoagulant better Warfarin better BID, twice daily; CI, confidence interval CKD chronic kidney disease; qd, once daily *Stage III CKD: estimated creatinine clearances ml/min for dabigatran and rivaroxaban; ml/min for apixaban. The width of the 90% CIs are estimated from published figures for dabigatran Adapted from Hart et al. Canadian Journal of Cardiology 2013;29:S71-S78
32 No dose adjustment of Apixaban is required in patients with mild or moderate impairment only 1 The recommended dose of apixaban is 5 mg taken orally twice daily (BD), swallowed with water, with or without food. Impaired renal function Mild or moderate renal impairment Severe renal impairment (creatinine clearance ml/min) Dialysis Renal failure (creatinine clearance <15 ml/min) SmPC recommendation No dose adjustment required The standard dose reduction to 2.5 mg BD for two or more of the following criteria applies: age 80 years; weight 60 kg; serum creatinine level 1.5 mg/dl (133 µmol/l) Dose reduction to 2.5 mg BD Not recommended Not recommended Note: ESC guidelines do not recommend the use of NOACs in patients with severe renal impairment (CrCl < 30 ml/min) 2 Rivaroxaban requires a dose reduction to 15 mg QD for moderate/severe renal impairment, and is not recommended in renal failure (Cr Cl<15 ml/min) 3 For dabigatran, the SMPC recommendation is that for moderate renal impairment, a dose of 110 mg BD be considered. Dabigatran is contraindicated in severe renal impairment (Cr Cl<30 ml/min) 4 1 Apixaban SmPC. Accessed Jan Camm AJ et al. European Heart Journal 2012;33: Rivaroxaban SmPC accessed Jan Dabigatran SmPC accessed Jan 2014
33 Recommendations in Guidelines?
34
35 EHRA guide Practical guidance on how to utilize the NOAC s The focus is on typical situations and challenges faced in clinical practice, such as - renal dysfunction - bleeding events - need for surgery - concomitant CHD - stroke despite adequate SPAF therapy European Heart Journal doi: /eurheartj/ehs253
36 Patients with chronic kidney disease Estimated t ½ and AUC NOAC plasma concentrations compared to healthy controls Heidbuchel et al.: EHRA Practice Guide 2015 Europace doi: /europace/euv309
37 NOACs in renal dysfunction Practical recommendations for dosing in chronic kidney disease Dabigatran Apixaban Edoxaban * Rivaroxaban When CrCl ml/min, 150 mg CrCl ml/min: 2.5 mg not available 15 mg OD when CrCl BID is possible (SmPC) but 110 mg BID is possible BID if high risk of bleeding (SmPC) Serum creatinine 1.5 mg/dl in or recommended (GL update)1 combination with age 80 Note: 75 mg BID approved in US years or weight 60 kg only# (SmPC) or with other yellow -If CrCl ml/min factor: 2.5 mg BID ml/min -If CrCl ml/min -And other orange factor (e.g. verapamil) *No EMA approval yet. Needs update after finalisation of SmPC; #No EMA indication. FDA recommendation based on pharmacokinetics. Carefully consider benefits and risks of this approach. Note that 75 mg capsules are not available in Europe for AF indication; Australian prescribing information Disclaimer: All NOACS should always be used in accordance with local prescribing authorization, which may or may not be the same as in Europe and the US 1. Camm et al, Eur Heart J 2012;33: ; Heidbuchel et al, Europace 2013;15: ; Heidbuchel et al, Eur Heart J 2013;34:
38 Bleeding risk with CrCL < 50 ml/min 45 J Am Soc Nephrol. 2014; 25:
39
40 Summary and Conclusions Patients with AF and moderate to severe renal impairment are at increased risk of stroke and also have an increased bleeding risk Studies indicate this population is undertreated Dabigatran, Rivaroxaban and apixaban: The efficacy and safety findings vs. warfarin in the overall population are maintained in patients with moderate renal impairment Also in the elderly, the benefits of apixaban vs. warfarin were consistent across the range of egfr The data suggest that apixaban may be particularly suited to address the unmet need for a more effective and safe stroke prevention in patients with AF and renal dysfunction.
41 Thank you for your attention 41
DIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationInsufficienza renale e DOAC
Insufficienza renale e DOAC Domenico Prisco DMSC, Università di Firenze SOD Patologia Medica, AOU Careggi Bologna 14 ottobre 2014 Ha ricevuto onorari per relazioni e partecipazione ad advisory board e
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationScientific news from the ESC congress 5 highlights
Scientific news from the ESC congress 5 highlights Prof. Dan Atar, MD Dept. of Cardiology B Oslo University Hospital, Norway Vice-President of the ESC (2014-2016) ESC Media Committee (2016-2018) ESC Treasurer/Secretary
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationNOACs Scegliere in Contesti Particolari
Gianluca Botto, FESC, FEHRA U.O.s. Elettrofisiologia ASST-Lariana, Como NOACs Scegliere in Contesti Particolari Presenter Disclosure Information Research support: Boston Scientific, Medtronic; St. Jude
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationPRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationRenal Function Considerations for Stroke Prevention in Atrial Fibrillation
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation Wednesday, March 28, 2018, 1:00PM ET Presenters: John Fanikos, RPh, MBA Curt Mahan, PharmD Paul Dobesh, PharmD, FCCP, BCPS Presenters
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationNOAC 2015: What Have We Learned?
NOAC 2015: What Have We Learned? Milan Gupta, MD Canadian Cardiovascular Research Network University of Toronto, McMaster University www.ccrnmd.com Disclosures Honoraria / Research Grants Abbott, Aegerion
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationSTROKE PREVENTION 5/11/2015. Stroke Incidence by Age. Cardiogenic Embolism is the most common cause of stroke
(%) (%) 5/11/15 STROKE PREVENTION Stroke Incidence by Age T H E G E N E R A L P R A C T I C E E D U C A T I O N D A Y U N I V E R S I T Y O F Q U E E N S L A N D 3 1 O C T O B E R 2 1 5 A S S O C I A T
More informationReal-World Insights from GARFIELD-AF Registry Presented at ESC Congress 2017
Real-World Insights from GARFIELD-AF Registry Presented at ESC Congress 2017 One of the aims of GARFIELD-AF is to assist physicians in their understanding of the risk of stroke in patients with atrial
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationClo$ng vs bleeding: not as simple as we would like. OACs for stroke preven:on: Too many choices?
Clo$ng vs bleeding: not as simple as we would like OACs for stroke preven:on: Too many choices? Paul Dorian University of Toronto St Michael s Hospital . Speaker Disclosure Form Paul Dorian Disclosures:
More informationModern Management in Primary Care (AF1)
Modern Management in Primary Care (AF1) Dr Ravi Assomull Consultant Cardiologist London North West Healthcare NHS Trust Dr Yassir Javaid Primary Care Cardiovascular Lead East Midlands Strategic Clinical
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationStroke prevention, Clinical trials
Received: 13 May 2016 Revised: 8 August 2016 Accepted: 18 August 2016 DOI 10.1002/clc.22596 REVIEWS Special considerations for therapeutic choice of non vitamin K antagonist oral anticoagulants for Japanese
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationNew oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials
New oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials Dimitri Richter, MD, FESC, FAHA Head of Cardiac Dept., Athens Euroclinic General Secretary of Hellenic Lipidology Society Member
More informationEfficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score
2138 HORI M et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Arrhythmia/Electrophysiology Efficacy and Safety of Dabigatran Etexilate
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationΧάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ»
Η ισορροπία ασφάλειας και αποτελεσματικότητας: Η συνέπεια στα αποτελέσματα των τυχαιοποιημένων κλινικών μελετών και των δεδομένων κλινικής πρακτικής της Απιξαμπάνης Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationAnticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet?
Anticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet? 16/06/2018 apr. Julie Hias Satellite symposium supported by the Alliance BMS/Pfizer 432BE18PR03459/ 180570 (Date of Preparation:
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More informationThe era of NOACs. (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul
The era of NOACs (non-vitamin K oral anticoagulants) in Clinical Pharmacy : Patrick Tilleul Head Pharmacist, Pitié Salpêtrière hospital Associate professor Paris Sorbonne University Disclosure Patrick
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationDirect Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD
Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Dr. Skinner serves as an Assistant Professor of Pharmacy Practice at Manchester University, and he is one of three Internal Medicine
More informationWhat evidence is there that variable clinical responses to PK parameters exist for NOACs? What conclusions can we draw from these data?
Is There A Role For Pharmacokinetic/Pharmacodynamics Guided Dosing For Novel Anticoagulants? The Heart House, Washington, DC, 3 December 2015 What evidence is there that variable clinical responses to
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More information